drugset / Trial / NCT01063283
Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC
RandomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see if higher dose of bevacizumab can be taken safely by some patients and if changes in the dose of bevacizumab have any effect on blood pressure.
Timeline
- Start
- 2010-03
- Primary completion
- 2016-06
- Completion
- 2016-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Comparator | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Comparator | Carboplatin | Small molecule | — | Intravenous |
| Comparator | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |